Abstract
Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed. Keywords: Dostarlimab, PD1 immunoglobulin, T - cell proliferation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
